These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 26892282)

  • 1. Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression Is Stroke Mimic.
    Goyal MS; Hoff BG; Williams J; Khoury N; Wiesehan R; Heitsch L; Panagos P; Vo KD; Benzinger T; Derdeyn CP; Lee JM; Ford AL
    Stroke; 2016 Apr; 47(4):1012-7. PubMed ID: 26892282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between MRI screening and CT-plus-MRI screening for thrombolysis within 3 h of ischemic stroke.
    Yoo SH; Kwon SU; Lee DH; Kim SJ; Kim JS; Kang DW
    J Neurol Sci; 2010 Jul; 294(1-2):119-23. PubMed ID: 20441993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Primary Imaging Modality-Computed Tomography or Magnetic Resonance Imaging-Influence Stroke Physicians' Certainty on Whether or Not to Give Thrombolysis to Randomized Acute Stroke Patients?
    Hansen CK; Christensen A; Rodgers H; Havsteen I; Kruuse C; Christensen H
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):926-935. PubMed ID: 29198901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
    Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in Door-to-Needle Time in Patients with Acute Ischemic Stroke via a Simple Stroke Activation Protocol.
    Tan BYQ; Ngiam NJH; Sunny S; Kong WY; Tam H; Sim TB; Leong BSH; Bhartendu C; Paliwal PR; Seet RCS; Chan BPL; Teoh HL; Sharma VK; Yeo LLL
    J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1539-1545. PubMed ID: 29422380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial body temperature in ischemic stroke: nonpotentiation of tissue-type plasminogen activator benefit and inverse association with severity.
    Kim SH; Saver JL
    Stroke; 2015 Jan; 46(1):132-6. PubMed ID: 25424482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systemized stroke code significantly reduced time intervals for using intravenous tissue plasminogen activator under magnetic resonance imaging screening.
    Sohn SW; Park HS; Cha JK; Nah HW; Kim DH; Kang MJ; Choi JH; Huh JT
    J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):465-72. PubMed ID: 25524016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a 1-year quality-improvement process to reduce door-to-needle time in acute ischemic stroke with MRI screening.
    Sablot D; Gaillard N; Colas C; Smadja P; Gely C; Dutray A; Bonnec JM; Jurici S; Farouil G; Ferraro-Allou A; Jantac M; Allou T; Pujol C; Olivier N; Laverdure A; Fadat B; Mas J; Dumitrana A; Garcia Y; Touzani H; Perucho P; Moulin T; Richard C; Heroum C; Bouly S; Sagnes-Raffy C; Heve D
    Rev Neurol (Paris); 2017; 173(1-2):47-54. PubMed ID: 28131535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening with MRI for Accurate and Rapid Stroke Treatment: SMART.
    Shah S; Luby M; Poole K; Morella T; Keller E; Benson RT; Lynch JK; Nadareishvili Z; Hsia AW
    Neurology; 2015 Jun; 84(24):2438-44. PubMed ID: 25972494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging-DRAGON score: 3-month outcome prediction after intravenous thrombolysis for anterior circulation stroke.
    Turc G; Apoil M; Naggara O; Calvet D; Lamy C; Tataru AM; Méder JF; Mas JL; Baron JC; Oppenheim C; Touzé E
    Stroke; 2013 May; 44(5):1323-8. PubMed ID: 23482603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Telestroke Treatment Times in an Expanding Network of Hospitals.
    Sanders KA; Patel R; Kiely JM; Gwynn MW; Johnston LH
    J Stroke Cerebrovasc Dis; 2016 Feb; 25(2):288-91. PubMed ID: 26654667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Impact of Implementation of a Stroke Protocol on Door-to-Needle Time in the Administration of Intravenous Tissue Plasminogen Activator.
    Hillen ME; He W; Al-Qudah Z; Wang W; Hidalgo A; Walia J
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1569-1572. PubMed ID: 28411038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.
    Lubeck DP; Danese MD; Duryea J; Halperin M; Tayama D; Yu E; Lalla D; Grotta JC
    Int J Stroke; 2016 Feb; 11(2):198-205. PubMed ID: 26783311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permeable Thrombi Are Associated With Higher Intravenous Recombinant Tissue-Type Plasminogen Activator Treatment Success in Patients With Acute Ischemic Stroke.
    Santos EM; Dankbaar JW; Treurniet KM; Horsch AD; Roos YB; Kappelle LJ; Niessen WJ; Majoie CB; Velthuis B; Marquering HA;
    Stroke; 2016 Aug; 47(8):2058-65. PubMed ID: 27338928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.